A platform study of DNA damage response inhibitors in combination with conventional radiotherapy in non-small cell lung cancer
Trial summary:
To assess the safety and determine the recommended phase II dose (RP2D) of DNA damage response inhibitors (DDRi) to be used in combination with radical thoracic radiotherapy in stage IIB/III non-small cell lung cancer (NSCLC). Five different inhibitors will be applied, each on a different study arm aiming to get approximately 30 patients in each experimental arm treated with DDRi + Radiotherapy and approximately 50-60 patients treated with RT alone. Total accrual is estimated to 210 patients in 6 years.
RT QA summary:
All QA activity will be streamlined with previous trial QA, where applicable. Please contact the RTTQA Group directly using the contact details below to discuss.
| QA Process | QA Activity | Required for Trial | Additional Details |
|---|---|---|---|
| Pre-Accrual | Facility Questionnaire |  | |
| Outlining Benchmark Case | |||
| Planning Benchmark Case | |||
| Dummy Run | | ||
| During Accrual | Individual Case Review | ||
| Data collection | | All patients | |
| Dosimetry | | ||
| QA Streamlining | | ADSCAN, Isotoxic IMRT |
RTTQA contact: concordeqa.enh-tr@nhs.net
Chief investigator: Dr Alastair Greystoke / Dr Corinne Faivre-Finn
Sponsor: University of Leeds ctru_concorde@leeds.ac.uk
Funder: CRUK, AstraZeneca